Dosing Rationale for Liraglutide in Type 2 Diabetes Mellitus: A Pharmacometric Assessment

The glucagon‐like peptide‐1 (GLP‐1) receptor agonist liraglutide was approved in 2010 by the US Food and Drug Administration (FDA) as an adjunct treatment to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. This article provides insights into the use of pharmacometric analyses for regulatory review with a focus on the dosing recommendations. The assessment was based on the totality of exploratory and confirmatory analysis of dose‐finding and pivotal clinical data and was structured around a set of key questions in accordance with current FDA review practice. For the pharmacometric review of liraglutide, the key questions focused on exposure‐response relationships for effects on fasting plasma glucose, hemoglobin A 1c , and calcitonin and on variability in exposure across demographic subgroups of patients. The importance of conducting exploratory exposure‐response analysis and population pharmacokinetic studies in clinical drug development to support dosing recommendations is highlighted.